Business Description
Hansa Biopharma AB
SIC : 2834
ISIN : SE0002148817
Share Class Description:
LTS:0RC7: Ordinary SharesTotal Employee Number:
131Compare
Compare
Traded in other countries / regions
HNSA.SwedenHNSBF.USA0RC7.UK24H.Germany IPO Date
2015-11-11Description
Hansa Biopharma AB is a Swedish commercial-stage biopharmaceutical company focused on treatments for rare immunological conditions. Its core technology is an antibody-cleaving enzyme platform designed to eliminate pathogenic IgG antibodies. The company's lead product, imlifidase, is a first-generation IgG-cleaving enzyme administered intravenously that inactivates all four IgG subclasses. Imlifidase is approved in the European Union under the brand name Idefirix for desensitization of highly sensitized adult kidney transplant patients. Hansa is also developing the platform for autoimmune diseases and gene therapy applications, and is advancing a next-generation enzyme candidate. The company generates revenue primarily through product sales of Idefirix in Europe, along with partnership and licensing arrangements. Hansa is headquartered in Lund, Sweden, and is listed on Nasdaq Stockholm.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.54 | |||||
Equity-to-Asset | -0.49 | |||||
Debt-to-Equity | -1.99 | |||||
Debt-to-EBITDA | -1.82 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.07 | |||||
Beneish M-Score | -3.76 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -7.3 | |||||
3-Year EBITDA Growth Rate | 28.2 | |||||
3-Year EPS without NRI Growth Rate | 23.7 | |||||
3-Year FCF Growth Rate | 15.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 15.64 | |||||
9-Day RSI | 27.5 | |||||
14-Day RSI | 36.39 | |||||
3-1 Month Momentum % | 30.04 | |||||
6-1 Month Momentum % | 36.64 | |||||
12-1 Month Momentum % | 37.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.25 | |||||
Quick Ratio | 1.23 | |||||
Cash Ratio | 1 | |||||
Days Inventory | 24.02 | |||||
Days Sales Outstanding | 206.96 | |||||
Days Payable | 243.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.9 | |||||
Shareholder Yield % | -0.48 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.32 | |||||
Operating Margin % | -310.93 | |||||
Net Margin % | -406.5 | |||||
EBITDA Margin % | -299.3 | |||||
FCF Margin % | -282.95 | |||||
OCF Margin % | -282.95 | |||||
ROA % | -77.35 | |||||
ROIC % | -81.48 | |||||
3-Year ROIIC % | 13.23 | |||||
ROC (Joel Greenblatt) % | -5037.58 | |||||
ROCE % | -98 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 20.61 | |||||
PS Ratio | 19.08 | |||||
EV-to-EBIT | -7.14 | |||||
EV-to-EBITDA | -7.29 | |||||
EV-to-Revenue | 21.82 | |||||
EV-to-Forward-Revenue | 23.16 | |||||
EV-to-FCF | -8.13 | |||||
Price-to-GF-Value | 1.66 | |||||
Price-to-Median-PS-Value | 0.06 | |||||
Earnings Yield (Greenblatt) % | -14 | |||||
FCF Yield % | -15.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hansa Biopharma AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 189.46 | ||
| EPS (TTM) (kr) | -7.912 | ||
| Beta | -0.0439 | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.51 | ||
| Volatility % | 54.43 | ||
| 14-Day RSI | 36.39 | ||
| 14-Day ATR (kr) | 1.355515 | ||
| 20-Day SMA (kr) | 42.5345 | ||
| 12-1 Month Momentum % | 37.26 | ||
| 52-Week Range (kr) | 23.57 - 48 | ||
| Shares Outstanding (Mil) | 99.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hansa Biopharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hansa Biopharma AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-11 08:00 | In 143 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-11 | In 142 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 | In 44 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 44 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-22 14:00 | 33.18 (+1.94%) | ||
| Second quarter earnings results for 2026 | 2026-07-22 | 33.18 (+1.94%) | ||
| Hansa Biopharma Capital Markets Day | 2026-06-25 09:00 | 33.60 (-0.24%) | ||
| General meeting for 2026 | 2026-06-01 14:30 | 34.09 (+1.28%) | ||
| Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation | 2026-05-27 08:00 | 33.31 (-3.28%) | ||
| First quarter earnings conference call for 2026 | 2026-04-23 14:00 | 27.24 (-2.92%) |
Show
Entries
Hansa Biopharma AB Frequently Asked Questions
What is Hansa Biopharma AB(LTS:0RC7)'s stock price today?
The current price of LTS:0RC7 is kr36.88. The 52 week high of LTS:0RC7 is kr48.00 and 52 week low is kr23.57.
When is next earnings date of Hansa Biopharma AB(LTS:0RC7)?
The next earnings date of Hansa Biopharma AB(LTS:0RC7) is 2026-11-05.
Does Hansa Biopharma AB(LTS:0RC7) pay dividends? If so, how much?
Hansa Biopharma AB(LTS:0RC7) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers